We recently published a list of 10 Firms Lead Rally on Impressive Q1 Earnings, Optimistic Outlooks. In this article, we are going to take a look at where Hims & Hers Health, Inc. (NYSE:HIMS) stands against other top performers on Thursday.
The stock market ended strong anew on Thursday, with all major indices finishing in the green territory, as investor sentiment was bolstered by a flurry of corporate earnings supported by better-than-expected performance from the technology giants.
The tech-heavy Nasdaq led the rally among all major indices, finishing up 1.52 percent. The S&P 500 clocked in a 0.63-percent gain, while the Dow Jones was up by 0.21 percent.
Ten companies also mimicked the broader market optimism following impressive earnings performance and an optimistic outlook for the rest of the year.
In this article, we have identified the 10 top performers on Thursday and detailed the reasons behind their gains.
To come up with the list, we considered only the stocks with a $2-billion market capitalization and $5-million trading volume.
A nurse in a telehealth platform talking with a patient on video call for consultation.
Hims & Hers Health, Inc. (NYSE:HIMS)
Hims & Hers saw its share prices jump by 9.24 percent on Thursday to end at $36.16 apiece as investors repositioned portfolios ahead of the release of its earnings performance next week.
According to a statement, Hims & Hers Health, Inc. (NYSE:HIMS) will announce its earnings results after the market closes on Monday, May 5, 2025, where investors will be closely watching out for the company’s updated outlook guidance for the rest of the year.
In recent news, Hims & Hers Health, Inc. (NYSE:HIMS) clinched a long-term deal with Novo Nordisk to jointly market the latter’s blockbuster weight loss drug, Wegovy.
Hims & Hers Health, Inc. (NYSE:HIMS) said that Americans can now access NovoCare Pharmacy directly through its platform, with a bundled offering of all dose strengths of Wegovy and a Hims & Hers membership, including access to 24/7 care, ongoing clinical support, and nutrition guidance, among others.
It can be learned that HIMS used to make a compounded knock-off version of the treatment that helped propel its sales over the past few years. It was later discontinued after the Food and Drug Administration announced that Novo Nordisk had already produced a sufficient supply of the treatment.
Overall, HIMS ranks 2nd on our list of top performers on Thursday. While we acknowledge the potential of HIMS as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than HIMS but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.
Disclosure: None. This article is originally published at Insider Monkey.
